Zepp Health Corp (ZEPP) SEC Filings & Earnings Calls
EquiReason read 5 Zepp Health Corp SEC filings in the last 12 months. Latest: 6-K on 2026-09-02 — Zepp Health reported Q2 2026 revenue of $63.5M (+6.9% YoY), gross margin 37.4% (+120 bps), net loss $11.3M (wider than $7.7M loss a year ago). Product mix improving with higher ASP.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 38.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
2 Sep 20266-KZepp Health reported Q2 2026 revenue of $63.5M (+6.9% YoY), gross margin 37.4% (+120 bps), net loss $11.3M (wider than $7.7M loss a year ago). Product mix improving with higher ASPs in T-Rex, Active, and Balance families. Q3 guidance: revenearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $64M | +7% y/y |
| Gross Margin · Q2-2026 | 37.4% | |
| Net Loss · Q2-2026 | $-11M | +47% y/y |
| Cash and Cash Equivalents · Q2-2026 | $106M | +12% y/y |
| Cumulative Debt Retired · Q2-2026 | $40M | |
| Share Repurchases (Cumulative) · Q2-2026 | $18M |
Guidance
Q3 2026 net revenues expected between US$68.0 million and US$73.0 million, compared with US$75.8 million in Q3 2025.
Q3 guidance implies potential YoY decline due to high comparison base, but management notes improving product mix and demand trends in July/August that will take time to reflect in revenue.
Risks flagged
Net loss widened to $11.3M from $7.7M due to FX headwinds and increased R&D/marketing investment.
“Net loss attributable to Zepp was US$11.3 million, compared with US$7.7 million in the same period of 2025. The benefits of higher revenue and improved gross margin were offset by foreign-exchange headwinds and increased investment in research and development, marketing and brand building.” · word for word
Supply constraints on Bip and Helio Strap limited revenue potential; Q3 guidance implies potential YoY decline.
“Bip and Helio Strap were constrained by supply during the second quarter. Q3 guidance $68-73M vs $75.8M in Q3 2025.”
9 Jun 20266-KZepp Health reports Q1 2026 revenue of US$51.5M, +33.8% YoY; gross margin 37.7% vs 37.3% YoY; provides Q2 2026 revenue guidance of US$63-68M (+6-14% YoY).earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $52M | +34% y/y |
| Gross margin · Q1-2026 | 37.7% | |
| Cash and cash equivalents and restricted cash · Q1-2026 | $103M | -1% y/y |
| Inventory · Q1-2026 | $63M |
Guidance
Q2 2026 revenue guidance: US$63.0M to US$68.0M, representing 6% to 14% YoY growth
Management expects Q2 2026 net revenues between US$63.0M and US$68.0M, representing YoY growth of approximately 6% to 14%.
Risks flagged
Elevated memory component costs and RMB appreciation pressured gross margin; first-quarter seasonality and entry-level product refresh also headwinds.
“Elevated memory component costs and RMB appreciation pressured the gross margin performance.” · word for word
24 Apr 202620-FZepp Health reported FY2025 results with revenue of $258.9M, net loss of $40.1M, and continued decline in VIE revenue contribution.earningsopen
Figures in the filing · each found in the filing text
| Third-party revenues · FY2025 | $259M | +42% y/y |
| Net loss attributable to Zepp Health Corporation's shareholders · FY2025 | $-40M | -47% y/y |
| Cash and cash equivalents · 2025-12-31 | $57M | -37% y/y |
| VIE revenue contribution · FY2025 | 8.0% | |
| Total assets · 2025-12-31 | $565M | +7% y/y |
| Total liabilities · 2025-12-31 | $350M | +27% y/y |
| Total equity · 2025-12-31 | $215M | -15% y/y |
Risks flagged
Customer concentration risk
“One customer (Company C) accounted for a significant portion of revenue and accounts receivable.”
Supply chain concentration risk
“Key components sourced from limited suppliers; supply shortages could disrupt operations.”
Regulatory risk in China
“VIE structure and PRC regulations create uncertainty; potential for adverse government action.”
Delisting risk
“ADS price has fallen below NYSE minimum; regained compliance but risk remains.”
Foreign exchange risk
“Exposure to EUR and RMB fluctuations; reporting currency changed to USD to mitigate.”
16 Mar 20266-KZepp Health Q4 2025 revenue $85.2M (+43% YoY), record gross margin 40.4% (+3.6pp YoY), net loss narrowed 70.2%. FY25 revenue $258.9M (+41.8% YoY). Q1 2026 guidance $50-55M (+30-43% YoY).earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $85M | +43% y/y |
| Gross margin · Q4-2025 | 40.4% | |
| GAAP net loss · Q4-2025 | $11M | -70% y/y |
| Adjusted net loss · Q4-2025 | $6M | -72% y/y |
| Cash and cash equivalents and restricted cash · Q4-2025 | $113M | +2% y/y |
| Inventory · Q4-2025 | $73M | -17% y/y |
| Full year revenue · FY2025 | $259M | +42% y/y |
| Full year gross margin · FY2025 | 38.3% | |
| Full year GAAP net loss · FY2025 | $40M | -47% y/y |
| Full year adjusted net loss · FY2025 | $32M | -44% y/y |
Guidance
Q1 2026 revenue guidance $50.0M-$55.0M, representing 30%-43% YoY growth
Q1 2026 revenue guidance implies strong YoY growth, with margin expansion trend expected to continue.
Risks flagged
Foreign exchange fluctuations, memory chip cost increases, and tariffs pose headwinds to gross margin.
“Gross margin more than offset headwinds from foreign currency fluctuations, memory chip cost increases and tariffs amid macroeconomic uncertainties.”
Increase in operating expenses due to strategic investments and provisions for sales channel optimization.
“US$5.2 million specially identified provisions for sales channel optimization and brand and intellectual property protection.” · word for word
5 Nov 20256-KQ3 2025 revenue $75.8M (+78.5% YoY), GAAP operating loss narrowed to $0.9M from $12.5M, adjusted operating income breakeven. Gross margin 38.2% (+2.0pp QoQ). Q4 2025 guidance $82-86M (+38-45% YoY). Cash $102.6M.earningsopen
Figures in the filing · each found in the filing text
| Revenues · Q3-2025 | $76M | +79% y/y |
| Gross margin · Q3-2025 | 38.2% | |
| GAAP operating income/(loss) · Q3-2025 | $-900000.00 | -93% y/y |
| Adjusted operating income/(loss) · Q3-2025 | $400000.00 | -104% y/y |
| Cash and cash equivalents and restricted cash · Q3-2025 | $103M | +8% y/y |
Guidance
Q4 2025 net revenues $82.0M-$86.0M, representing 38%-45% YoY growth
Q4 guidance implies continued strong growth (+38-45% YoY) from Q3's 78.5% YoY growth, indicating sustained demand momentum.
Risks flagged
Supply constraints on Amazfit Helio Strap and end-of-quarter typhoon delayed some sales.
“Revenue increase was partially offset by some supply constraints on Amazfit Helio Strap, as well as an end-of-quarter typhoon.” · word for word
U.S. tariffs on China-manufactured goods impacted gross margin via front-loaded shipments.
“Impact of front-loaded shipments ahead of U.S. tariffs on China-manufactured goods.” · word for word
Zepp Health Corp — questions
- What did Zepp Health Corp file recently?
- 5 SEC filings in the last 12 months. Latest: 6-K on 2026-09-02 — Zepp Health reported Q2 2026 revenue of $63.5M (+6.9% YoY), gross margin 37.4% (+120 bps), net loss $11.3M (wider than $7.7M loss a year ago). Product mix improving with higher ASPs in T-Rex, Active, and Balance families. Q3 guidance: reven
Every figure on this page comes from Zepp Health Corp's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.